Skip to main content

Table 7 Adverse events in patients treated as second-or-greater line setting (n = 102)

From: Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

Adverse event

G0

G1

G2

G3

G4

NE

All grades (%)

Grade 3/4 (%)

Leucocyte

6

5

13

34

42

2

92.2

74.5

Neutrophils

7

4

12

22

54

3

90.2

74.5

Hemoglobin

17

33

30

18

2

2

81.4

19.6

Platelets

36

18

12

21

13

2

62.7

33.3

AST

65

32

1

2

0

2

34.3

2.0

ALT

60

30

8

2

0

2

39.2

2.0

Anorexia

39

45

10

2

0

6

55.9

2.0

Nausea

48

38

10

1

0

5

48.0

1.0

Vomiting

77

17

3

0

0

5

19.6

0.0

Diarrhea

86

9

1

1

0

5

10.8

1.0

Fatigue

36

47

10

5

0

4

60.8

4.9

Febrile neutropenia

91

0

0

10

0

1

9.8

9.8

Fever

73

16

11

0

0

2

26.5

0.0

Infection

89

4

4

3

1

1

11.8

3.9

Dyspnea

93

4

1

3

0

1

7.8

2.9

Interstitial pneumonia

94

2

1

4

0

1

6.9

3.9

Neuropathy

96

0

5

0

0

1

4.9

0.0

Rash

90

2

5

4

0

1

10.8

3.9

Edema

101

0

1

0

0

0

1.0

0.0

Mucositis

99

1

2

0

0

0

2.9

0.0

Allergic reaction

100

0

2

0

0

0

2.0

0.0

  1. AST aspartate transaminase, ALT alanine aminotransferase